2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchBiochemically recurrent prostate cancerPositron emission tomographyPSMA-PETProstate cancerEmission tomographyCost-effectiveTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission tomography imagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiaries
2021
A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: e17003-e17003. DOI: 10.1200/jco.2021.39.15_suppl.e17003.Peer-Reviewed Original ResearchF-DCFPyL PET/CTProstate cancerF-DCFPyLPositron emission tomographyConventional imagingM1 diseaseBone scintigraphyStaging of PCaHigh-risk prostate cancerWhole-body bone scintigraphyM1 stage diseasePhase 2/3 studyCT detection rateMajority of patientsPET/CTLocoregional diseaseRadiologic evidenceStage diseaseLocal recurrenceMetastatic diseasePelvic LNSingle doseTNM stagingImaging reviewLesion countsA prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Durack J, Alva A, Preston M, Pouliot F, Saperstein L, Carroll P, Pienta K, Rowe S, Patnaik A, Probst S, Stambler N, Jensen J, Wong V, Siegel B, Morris M. A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging. Journal Of Clinical Oncology 2021, 39: 32-32. DOI: 10.1200/jco.2021.39.6_suppl.32.Peer-Reviewed Original ResearchF-DCFPyL PET/CTProstate cancerF-DCFPyLPositron emission tomographyConventional imagingM1 diseaseBone scintigraphyPhase II/III studyStaging of PCaHigh-risk prostate cancerWhole-body bone scintigraphyM1 stage diseaseCT detection rateMajority of patientsPET/CTLocoregional diseaseRadiologic evidenceIII studyStage diseaseLocal recurrenceMetastatic diseasePelvic LNSingle doseTNM stagingImaging review
2020
A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.
Pouliot F, Carroll P, Probst S, Pienta K, Rowe S, Saperstein L, Siegel B, Patnaik A, Preston M, Alva A, Gorin M, Morris M. A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT. Journal Of Clinical Oncology 2020, 38: 9-9. DOI: 10.1200/jco.2020.38.6_suppl.9.Peer-Reviewed Original ResearchHigh-risk prostate cancerF-DCFPyL PET/CTPET/CTRisk prostate cancerF-DCFPyLProstate cancerPositron emission tomographyM1 diseaseInitial stagingMetastatic lesionsPET/CT detection rateStandard cross-sectional imagingMetastasis detection rateDistant metastatic lesionsCT detection rateMetastatic prostate cancerCross-sectional imagingCurrent imaging modalitiesPositive predictive valueDetection rateEvaluable ptsPelvic LNsN1 diseaseMetastatic diseasePelvic LN
2019
A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).
Morris M, Pouliot F, Saperstein L, Rowe S, Gorin M, Josephson D, Wong J, Carroll P, Lin T, Stambler N, Wong V, Jensen J, Siegel B. A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). Journal Of Clinical Oncology 2019, 37: tps5093-tps5093. DOI: 10.1200/jco.2019.37.15_suppl.tps5093.Peer-Reviewed Original ResearchF-DCFPyL PET/CTPET/CTRecurrent prostate cancerMetastatic prostate cancerProstate cancerF-DCFPyLPositron emission tomographyClinical impactDiagnostic performancePET/CT resultsEquivocal conventional imagingOpen-label studyWhole-body PET/CTProstate-specific membrane antigenYears of ageUnmet diagnostic needsEligible patientsF-fluciclovineDefinitive therapyBaseline PSAMulticenter studyDetection rateProstate adenocarcinomaPatient managementC-choline